US Car Dealers Reeling from CDK Global Cyberattack by Lilu Anderson 25.06.2024 "Cyberattack on CDK Global by ransomware group BlackSuit disrupts operations of major US car dealers like Lithia Motors and AutoNation."
Top 5 Meme Coins to Buy Now: 2024’s Best Picks by John Darbie 25.06.2024 Explore 2024’s top meme coins: ButtChain, catwifhat, Pepe Coin, Bonk, and Mog Coin. Dive into their features, market appeal, and ...
Airbus Faces Delays & Cuts Delivery Targets Amid Shortages by Mark Eisenberg 25.06.2024 Airbus cuts 2024 airplane delivery target to 770 from 800 and delays 75 narrow-body jets/month production goal to 2027 due ...
AI in Ultrasound Imaging Market to Hit $1733M by 2031 by Lilu Anderson 25.06.2024 Artificial Intelligence in Ultrasound Imaging Market to grow from USD 889.16 million in 2023 to USD 1733.08 million by 2031 ...
Microsoft-G42 Deal Cuts Huawei Ties, Welcomed by White House by Mark Eisenberg 25.06.2024 Microsoft's $1.5B investment in AI firm G42, praised by the White House for cutting Huawei ties, boosts security and U.S.-UAE ...
New EU Nature Law: Urgent Call for Financing Conservation by Mark Eisenberg 24.06.2024 Europe's new Nature Restoration Law aims to restore 20% of natural areas by 2030; urgent financing needs remain. Discover how ...
UBS: S&P 500 Earnings to Surge 11%, AI Investments Soar by Mark Eisenberg 24.06.2024 "UBS forecasts 11% earnings growth for S&P 500 in 2024, driven by AI and economic strength, with favorable Fed policies ...
NIS 2 Compliance with WatchGuard: Download Free Report Today by Lilu Anderson 24.06.2024 "EU launches NIS 2 to bolster cybersecurity, expanding coverage and tightening incident reporting. Essential for businesses in the EU."
Boeing Stock: Q2 Catalysts to Watch Before July 7 by Mark Eisenberg 24.06.2024 "Boeing stock watch: DOJ decision by July 7, Spirit AeroSystems deal, CEO search, and key 737 MAX production goals for ...
ResMed, Inspire Medical Drop After Lilly’s Zepbound Study by Mark Eisenberg 24.06.2024 "ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...